

# Modern Slavery Act Statement

## Introduction

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and is published on behalf of the Kelso Pharma group of companies.

## Our Organisation

Kelso Pharma is headquartered in the United Kingdom and our vision is to bring innovative, value added, specialty branded medicines to the UK and EU markets, bringing benefits to patients and reducing the cost burden to healthcare systems.

## Our Supply Chain

Kelso Pharma uses a relatively small number of suppliers who supply active pharmaceutical ingredients, excipients and packaging to manufacture and produce our products in a highly regulated and quality-controlled environment.

Kelso Pharma is committed to continuously improving its practices to identify and eliminate any human trafficking or slavery in its supply chain and to acting ethically and with integrity as an employer and in all its business relationships.

## Due Diligence

We will monitor our suppliers and assess any risks in our supply chain on a regular basis whether by ourselves or through third parties.

## Training

Kelso Pharma will seek to provide training and guidance to those members of its organisation who have direct responsibility for the supply chain and is committed to continuously reviewing and enhancing our policies and procedures to help identify, prevent and mitigate any risks of modern slavery or human trafficking in our supply chain.

## Approval

This statement has been approved by the Board of Directors of Kelso Group Limited the parent company of the Kelso Pharma group of companies and signed on their behalf for the year ending 31 December 2021.

Dr Thomas Stratford

Chief Executive Officer